HomeUSANewVale Capital Closes $167M Fund

NewVale Capital Closes $167M Fund

NewVale Capital

NewVale Capital, LLC, a Boulder, CO-based growth equity firm focused on investments in the services architecture underpinning the life science industry, closed its inaugural fund, at $167m.

Backers included institutional limited partners across university endowments, foundations, insurance companies, fund of funds and family offices, alongside recognized pharmaceutical executives and investors. 

The vehicle will accelerate the growth of proven pharmaceutical services companies that play an essential role in bringing medicines to patients.

Led by Todd Holmes, Founder and Managing Partner, NewVale invests in services, software, and technologies – the infrastructure of life sciences – that have a proven return on investment for pharmaceutical customers, helping to accelerate timelines, reduce costs and improve quality. With nearly $200m total under management (including co-investment special purpose vehicles,) the firm makes investments of between $10m and $50m in growth companies across the continuum of the pharmaceutical value chain, including discovery, clinical, manufacturing, regulatory and commercialization.

NewVale led:

  • a $20m growth financing to expand the availability of Aizon’s machine learning software, which has been proven to increase productivity and reduce batch errors in the pharmaceutical manufacturing process
  • a $45m growth financing in Argonaut Manufacturing Services to meet the need for clinical and commercial sterile fill/finish capabilities of small- and medium-sized biopharmaceutical companies
  • a $14m growth financing to Beaconcure to provide the pharmaceutical and contract research industry with a novel software platform that reduces the time and cost of the biostatistical validation process across all clinical trials.